TAK1/MAP4K2 inhibitor 1

TAK1/MAP4K2 抑制剂 1

AKOS016012030 | n-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-((6-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)benzamide | F84885 | BenzaMide, N-[4-[(4-ethyl-1-piperazinyl)Methyl]-3-(trifluoroMethyl)phenyl]-4-Methyl-3-[(6-Methyl

TAK1/MAP4K2 inhibitor 1

T648184-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 ( TAK1 ) and mitogen-activated protein kinase kinase kinase kinase 2 ( MAP4K2 ) inhibitor, with IC 50 s of 41.1 nM and 18.2 nM, respectively. In Vivo TAK1/MAP4K2 inhibitor 1 has moderate terminal elimination half-life (t 1/2 =2.94 h for mice (1 mg/kg, iv)) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:TAK1 41.1 nM (IC 50 ) MAP4K2 18.2 nM (IC 50 )

TAK1/MAP4K2 抑制剂 1 是一种强效的 TGFβ 激活激酶 1（TAK1）和丝裂原活化蛋白激酶激酶 2（MAP4K2）双重抑制剂，其 IC 50 s 分别为 41.1 nM 和 18.2 nM。

1315330-11-0

C29H31F3N6O2

552.59 g/mol

71254032

CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=NC=NC5=C4C=C(N5)C)C(F)(F)F

N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]benzamide

1S/C29H31F3N6O2/c1-4-37-9-11-38(12-10-37)16-21-7-8-22(15-24(21)29(30,31)32)36-27(39)20-6-5-18(2)25(14-20)40-28-23-13-19(3)35-26(23)33-17-34-28/h5-8,13-15,17H,4,9-12,16H2,1-3H3,(H,36,39)(H,33,34,35)

RWNAOXLCVXJMGM-UHFFFAOYSA-N

CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=NC=NC5=C4C=C(N5)C)C(F)(F)F

71254032

1315330-11-0

DMSO : 50 mg/mL (90.48 mM; Need ultrasonic)

2

9

7

552.246 Da

552.246 Da

86.400 Ų

40

0

841

0

1

5